Physician profile
Oded Zmora
NPI 1750485207
$128.16
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.37 · 2021: $59.01 · 2022: $13.80 · 2023: $17.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.22 | 2021 | |
| Astellas Pharma US INC | $24.87 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.84 | 2021 | |
| Novo Nordisk INC | $17.98 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.80 | 2022 | |
| Lilly USA, LLC | $12.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oded Zmora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.